病毒載體和質體DNA:各種技術和全球市場
市場調查報告書
商品編碼
1452908

病毒載體和質體DNA:各種技術和全球市場

Viral Vector and Plasmid DNA: Technologies and Global Markets

出版日期: | 出版商: BCC Research | 英文 128 Pages | 訂單完成後即時交付

價格

全球病毒載體和質體DNA市場規模預計將從2023年的29億美元成長到2028年終的71億美元,預測期間內年複合成長率為19.7%。

病毒載體技術市場預計將從2023年的18億美元成長到2028年終的45億美元,同期年複合成長率為20.7%。此外,質體DNA技術市場預計將從2023年的11億美元成長到2028年底的26億美元,年複合成長率為17.9%。

本報告調查了全球病毒載體和質體DNA市場,並提供了市場概況,市場影響因素和市場機會分析,市場規模的推移和預測,各個細分和地區的詳細分析,臨床試驗和專利趨勢、競爭狀況、主要公司概況等彙整資訊。

目錄

第1章 執行摘要

  • 市場展望
  • 調查範圍
  • 市場摘要

第2章 市場概況

  • 病毒技術
  • 細胞和基因治療

第3章 市場動態

  • 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 課題

第4章 新興科技與發展

  • 概述
  • 病毒載體生產的人工智慧
  • doggybone DNA
  • FRAGment Recycler:質體DNA 合成新技術
  • 專利
  • 製造商的專利擁有情形
  • 臨床試驗
  • 病毒載體和質體DNA技術的臨床試驗

第5章 全球病毒載體與質體DNA技術市場

  • 分類
  • 市場區隔:依產品類型
  • 市場區隔:依最終用戶
  • 研究機構
  • 製藥和生物製藥公司
  • 市場區隔:依應用
  • 癌症
  • 遺傳疾病
  • 感染疾病
  • 心血管疾病
  • 其他疾病
  • 地域分佈
  • 市場區隔:依地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 競爭訊息

  • 產業場景
  • 企業市場占有率
  • 企業之間的競爭狀況
  • 競爭格局:病毒載體
  • 競爭格局:質體DNA

第7章 病毒載體和質體DNA 技術市場的永續性:ESG 視角

  • 環境因素
  • 社會因素
  • 管治因素
  • 主要企業ESG表現
  • 主要企業ESG表現
  • Lonza:ESG 績效
  • Thermo Fisher Scientific:ESG 績效
  • 結論

第8章 附錄

  • 調查方法
  • 縮寫詞
  • 參考
  • 公司簡介
  • AGILENT TECHNOLOGIES INC.
  • BLUEBIRD BIO INC.
  • CATALENT INC.
  • DANAHER CORP.
  • FUJIFILM HOLDINGS CORP.
  • GENSCRIPT
  • GILEAD SCIENCES INC.
  • LONZA
  • NOVARTIS AG
  • OXFORD BIOMEDICA PLC
  • PLASMIDFACTORY GMBH
  • REGENXBIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • VGXI INC.
Product Code: BIO192B

The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.

The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.

The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

  • 93 data tables and 47 additional tables
  • An overview of the global market for viral vector and plasmid DNA
  • Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
  • A look at the innovations, technological advances, and product launches from leading companies
  • Analysis of the industry's regulatory framework and policies, and its product pipeline
  • Discussion of ESG challenges and ESG practices
  • Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
  • Profiles of the leading players in the industry

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Viral Technology
  • Cell and Gene Therapy

Chapter 3 Market Dynamics

  • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Chapter 4 Emerging Technologies and Developments

  • Overview
  • AI in Viral Vector Production
  • Doggy Bone DNA
  • FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
  • Patents
  • Patent Holdings by Manufacturer
  • Clinical Trials
  • Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

  • Segmentation Breakdown
  • Market Breakdown by Product Type
  • Market Breakdown by End User
  • Research Institutes
  • Pharmaceutical and Biopharmaceutical Companies
  • Market Breakdown by Application
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Other Diseases
  • Geographic Breakdown
  • Market Breakdown by Region
  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Industry Scenario
  • Company Shares
  • Competitive Landscape among Companies
  • Competitive Landscape in Viral Vectors
  • Competitive Landscape in Plasmid DNA

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

  • Introduction
  • Environmental Factors
  • Social Factors
  • Governance Factors
  • ESG Performance among Major Companies
  • ESG Performance of Select Companies
  • Lonza: ESG Performance
  • Thermo Fisher Scientific: ESG Performance
  • Conclusion

Chapter 8 Appendix

  • Research Methodology
  • Acronyms
  • References
  • Company Profiles
  • AGILENT TECHNOLOGIES INC.
  • BLUEBIRD BIO INC.
  • CATALENT INC.
  • DANAHER CORP.
  • FUJIFILM HOLDINGS CORP.
  • GENSCRIPT
  • GILEAD SCIENCES INC.
  • LONZA
  • NOVARTIS AG
  • OXFORD BIOMEDICA PLC
  • PLASMIDFACTORY GMBH
  • REGENXBIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • VGXI INC.

List of Tables

  • Summary Table : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 1 : Global Incidence of All Cancers, by WHO Region, 2022-2050
  • Table 2 : Global Incidence of Leukemia, by WHO Region, 2022-2050
  • Table 3 : Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022-2050
  • Table 4 : Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050
  • Table 5 : Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050
  • Table 6 : Patents Held by Oxford Biomedica, 2021-Present
  • Table 7 : Selected Patents Held by Lonza, 2021-Present
  • Table 8 : Patents Held by Regenxbio, 2021-Present
  • Table 9 : Selected Clinical Trials, by Viral Vector Type
  • Table 10 : Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
  • Table 11 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 12 : Global Market for Plasmid DNA Technology, by Region, Through 2028
  • Table 13 : Global Market for Viral Vector Technology, by Region, Through 2028
  • Table 14 : Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028
  • Table 15 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028
  • Table 16 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028
  • Table 17 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028
  • Table 18 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028
  • Table 19 : Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
  • Table 20 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 21 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028
  • Table 22 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 23 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
  • Table 24 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 25 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
  • Table 26 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 27 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
  • Table 28 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 29 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
  • Table 30 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
  • Table 31 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 32 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028
  • Table 33 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 34 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
  • Table 35 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 36 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
  • Table 37 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 38 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
  • Table 39 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 40 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
  • Table 41 : RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
  • Table 42 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 43 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028
  • Table 44 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 45 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
  • Table 46 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 47 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
  • Table 48 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 49 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
  • Table 50 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 51 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
  • Table 52 : RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
  • Table 53 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 54 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028
  • Table 55 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 56 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
  • Table 57 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 58 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
  • Table 59 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 60 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
  • Table 61 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 62 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
  • Table 63 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
  • Table 64 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 65 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028
  • Table 66 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 67 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
  • Table 68 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 69 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
  • Table 70 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 71 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
  • Table 72 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 73 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028
  • Table 74 : RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
  • Table 75 : Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
  • Table 76 : North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 77 : North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
  • Table 78 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 79 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
  • Table 80 : European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 81 : European Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
  • Table 82 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 83 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
  • Table 84 : RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
  • Table 85 : ESG Rankings of Major Companies, 2024*
  • Table 86 : Lonza: ESG Performance
  • Table 87 : Thermo Fisher Scientific Inc.: ESG Performance
  • Table 88 : Acronyms Used in This Report
  • Table 89 : Agilent Technologies Inc.: Company Snapshot
  • Table 90 : Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022
  • Table 91 : Agilent Technologies Inc.: Product Portfolio
  • Table 92 : Agilent Technologies Inc.: News/Key Developments, 2023
  • Table 93 : Bluebird Bio Inc.: Company Snapshot
  • Table 94 : Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
  • Table 95 : Bluebird Bio Inc.: Product Portfolio
  • Table 96 : Bluebird Bio Inc.: Key News/Developments, 2022
  • Table 97 : Catalent Inc.: Company Snapshot
  • Table 98 : Catalent Inc.: Financial Performance, FY 2021 and 2022
  • Table 99 : Catalent Inc.: Product Portfolio
  • Table 100 : Catalent Inc.: Key News/Developments, 2021-2024
  • Table 101 : Danaher Corp.: Company Snapshot
  • Table 102 : Danaher Corp.: Financial Performance, FY 2021 and 2022
  • Table 103 : Danaher Corp.: Product Portfolio
  • Table 104 : Danaher Corp.: News/Key Developments, 2022
  • Table 105 : Fujifilm Holdings Corp.: Company Snapshot
  • Table 106 : Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022
  • Table 107 : Fujifilm Holdings Corp.: Product Portfolio
  • Table 108 : Fujifilm Holdings Corp.: News/Key Developments, 2022
  • Table 109 : GenScript: Company Snapshot
  • Table 110 : GenScript: Financial Performance, FY 2021 and 2022
  • Table 111 : GenScript: Product Portfolio
  • Table 112 : GenScript: News/Key Developments, 2023
  • Table 113 : Gilead Sciences Inc.: Company Snapshot
  • Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
  • Table 115 : Gilead Sciences Inc.: Product Portfolio
  • Table 116 : Gilead Sciences Inc.: News/Key Developments, FY 2021-2022
  • Table 117 : Lonza: Company Snapshot
  • Table 118 : Lonza: Financial Performance, FY 2021 and 2022
  • Table 119 : Lonza: Product Portfolio
  • Table 120 : Lonza: News/Key Developments, FY 2022
  • Table 121 : Novartis AG: Company Snapshot
  • Table 122 : Novartis AG: Financial Performance, FY 2021 and 2022
  • Table 123 : Novartis AG: Product Portfolio
  • Table 124 : Novartis AG: News/Key Developments, FY 2022
  • Table 125 : Oxford Biomedica Plc: Company Snapshot
  • Table 126 : Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
  • Table 127 : Oxford Biomedica Plc: Product Portfolio
  • Table 128 : Oxford Biomedica Plc: News/Key Developments, FY 2022
  • Table 129 : PlasmidFactory GmbH: Company Snapshot
  • Table 130 : PlasmidFactory GmbH: Product Portfolio
  • Table 131 : Regenxbio Inc.: Company Snapshot
  • Table 132 : Regenxbio Inc: Financial Performance, FY 2021 and 2022
  • Table 133 : Regenxbio Inc: Product Portfolio
  • Table 134 : Regenxbio Inc.: News/Key Developments, FY 2022
  • Table 135 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 136 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
  • Table 137 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 138 : VGXI Inc.: Company Snapshot
  • Table 139 : VGXI Inc.: Product Portfolio

List of Figures

  • Summary Figure A : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
  • Summary Figure B : Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022
  • Figure 1 : Viral Vector and Plasmid DNA Technologies: Market Dynamics
  • Figure 2 : Approved Cell and Gene Therapy Product Count, 2003 to the Present
  • Figure 3 : Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies
  • Figure 4 : Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022
  • Figure 5 : Global Company Market Shares of Viral Vectors, 2022
  • Figure 6 : Global Company Market Shares of Plasmid DNA, 2022
  • Figure 7 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022
  • Figure 8 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2022
  • Figure 9 : Catalent Inc.: Revenue Share, by Business Unit, FY 2022
  • Figure 10 : Catalent Inc.: Revenue Share, by Country/Region, FY 2022
  • Figure 11 : Danaher Corp.: Revenue Share, by Business Unit, FY 2022
  • Figure 12 : Danaher Corp.: Revenue Share, by Country/Region, FY 2022
  • Figure 13 : Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022
  • Figure 14 : Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022
  • Figure 15 : GenScript: Revenue Share, by Business Unit, FY 2022
  • Figure 16 : GenScript: Revenue Share, by Country/Region, FY 2022
  • Figure 17 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022
  • Figure 18 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022
  • Figure 19 : Lonza: Revenue Share, by Business Unit, FY 2022
  • Figure 20 : Lonza: Revenue Share, by Country/Region, FY 2022
  • Figure 21 : Novartis AG: Revenue Share, by Business Unit, FY 2022
  • Figure 22 : Novartis AG: Revenue Share, by Country/Region, FY 2022
  • Figure 23 : Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022
  • Figure 24 : Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022
  • Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022
  • Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022